IP Library Granted Patent US 7,662,148
Granted Patent B2
US 7,662,148 · App. 10/987,542 · Granted Feb 16, 2010

Systems and methods for intrastromal scanning patterns

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,148
App. No.
10/987,542
Granted
Feb 16, 2010
Kind
B2
Abstract

A method for photodisrupting a preselected subsurface volume of corneal tissue to alter a cornea's refractive properties is disclosed. Specifically, at least one stromal volume having a substantially conical shaped surface is photodisrupted. For this purpose, a laser device having a laser source, laser scanner and one or more optical elements is typically used. In one embodiment, a plurality of stromal volumes, with each stromal volume having a substantially conical shaped surface, is sequentially photodisrupted to form a contiguous stromal cavity. In a particular implementation, each conical shaped surface defines a cone axis that is aligned to be co-linear with a reference axis that passes through the anterior surface of the eye and may be aligned orthogonally to the anterior surface of the eye.

Claims (23)

1. A method for intrastromal refractive treatment of an eye, the eye having an anterior surface and a stroma, the method comprising the steps of:

establishing a frame of reference for the eye, wherein the frame of reference includes a reference axis passing through the anterior surface of the eye and aligned substantially orthogonally thereto;

directing a laser beam to a subsurface focal point in the stroma at a radial distance from the reference axis to photodisrupt stromal tissue at the focal point; and

scanning the subsurface focal point along a predetermined path to photodisrupt a stromal volume, wherein the stromal volume is bounded by substantially parallel conical shaped surfaces mutually defining a cone axis, with the cone axis being co-linear with the reference axis.

2. A method as recited in claim 1 wherein said conical shaped surfaces are a first conical shaped surface and a second conical shaped surface and said first conical shaped surface is a portion of a right circular cone.

3. A method as recited in claim 2 wherein the right circular cone defines a vertex and the first conical shaped surface includes the vertex.

4. A method as recited in claim 2 wherein the eye has an optical axis and the reference axis is substantially co-linear with the optical axis.

5. A method as recited in claim 2 wherein the right circular cone defines a cone angle and the cone angle is in the range of 0 degrees to 50 degrees.

6. A method as recited in claim 1 wherein the predetermined path includes focal point displacements characterized by displacement vectors having a nonzero component parallel to the reference axis.

7. A method as recited in claim 1 wherein the predetermined path includes focal point displacements characterized by displacement vectors having a nonzero azimuthal component relative to the reference axis.

8. A method as recited in claim 1 wherein stromal tissue is photodisrupted along the predetermined path at an initial focal point location and a final focal point location, and wherein the initial focal point location is positioned further from the anterior surface of the eye than the final focal point location.

9. A method as recited in claim 1 wherein the stromal volume is a first stromal volume and the method further comprises the step of scanning a focal point along a predetermined path to photodisrupt a second stromal volume, the second stromal volume having a substantially conical shaped surface.

10. A method as recited in claim 1 wherein said scanning step photodisrupts a plurality of stromal volumes to create a contiguous lenticular shaped cavity, and wherein each stromal volume is bounded by substantially parallel conical shaped surfaces mutually defining a cone axis, with the cone axis being co-linear with the reference axis.

11. A method of intrastromal refractive treatment for an eye, the eye having a stroma, the method comprising the steps of:

directing a laser beam to a subsurface focal point in the stroma to photodisrupt stromal tissue at the focal point;

scanning the focal point along a first predetermined path to photodisrupt a first stromal volume, the first stromal volume having a substantially first conical shaped surface; and

moving the focal point along a second predetermined path to photodisrupt a second stromal volume, the second stromal volume having a substantially second conical shaped surface and being contiguous with the first stromal volume.

12. A method as recited in claim 11 wherein the substantially first conical shaped surface is a portion of a first right circular cone and the substantially second conical shaped surface is a portion of a second right circular cone.

13. A method as recited in claim 12 wherein the first right circular cone defines a vertex and the first conical shaped surface includes the vertex.

14. A method as recited in claim 12 wherein the eye has an optical axis, the first cone defines a first cone axis, the second cone defines a second cone axis, and wherein the first and second cone axes are co-linear with the optical axis.

15. A method as recited in claim 12 wherein the eye has an anterior surface and an optical axis, the first right circular cone defines a first vertex, the second right circular cone defines a second vertex, the scanning step is performed before the moving step, and wherein the first and second vertex are located on the optical axis with the first vertex located further from the anterior surface than the second vertex.

16. A method as recited in claim 15 wherein the second conical shaped surface includes the second vertex.

17. A method as recited in claim 11 wherein the substantially first and second conical shaped surface defines a cone axis and subtends an azimuthal angle, α, about the cone axis of less than three hundred sixty degrees (α<360 degrees).

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 10, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023065/0970 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 023065/0012 →
CHANGE OF NAME Recorded Aug 5, 2009
From: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
To: 20/10 PERFECT VISION AG
Reel/Frame 023056/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2004
From: KUHN, TOBIAS; LOESEL, FRIEDER
To: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
Reel/Frame 015485/0793 →